hepatomiR cACLD Study

Launched by KARL LANDSTEINER UNIVERSITY OF HEALTH SCIENCES · May 24, 2024

Keywords

ClinConnect Summary

The hepatomiR cACLD Study is a clinical trial that aims to learn more about a test called hepatomiR, which helps doctors understand liver-related health issues in patients with chronic liver disease (CLD) and cirrhosis. The study focuses on identifying specific events, such as fluid buildup in the abdomen (ascites), bleeding from enlarged veins (variceal hemorrhage), and confusion due to liver problems (hepatic encephalopathy). By gathering this information, researchers hope to improve how we manage the risks and treatment options for patients with these conditions.

To participate in this study, you must be at least 18 years old and have been diagnosed with chronic liver disease for more than six months. You also need to receive care at the Clinical Department of Internal Medicine II at the University Hospital in St. Pölten. If you join, you will be asked to sign a consent form and may undergo tests to help researchers gather valuable data about your liver health. This study is currently recruiting participants of all genders, and it’s an opportunity to contribute to important research that could benefit future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Chronic liver disease (more than 6 months)
• • LSM ≥ 10 kPa
• • Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten
• • Signed patient consent form
• Exclusion Criteria:
• • Age older than 18 years
• • Pregnancy
• • Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and/or extrahepatic spread

Trial Officials